Subcutaneous House Dust Mite Immunotherapy Effectiveness and Safety in a Paediatric Population: A Prospective Real-Life Study
Authors:
- Inmaculada Buendía JiménezIJInmaculada Buendía Jiménez
- María Matas RosMRMaría Matas Ros
- Teresa Garriga-BarautTGTeresa Garriga-Baraut
- María Araceli Caballero-RabascoMCMaría Araceli Caballero-Rabasco
- Amalui Vásquez PérezAPAmalui Vásquez Pérez
- Laura Valdesoiro-NavarreteLVLaura Valdesoiro-Navarrete
- Magdalena Lluch PérezMPMagdalena Lluch Pérez
- Jesús VilloriaJVJesús Villoria
- Alfons Malet i CasajuanaACAlfons Malet i Casajuana
Open Access
- 12 June 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4188
Abstract
Background/Objectives: Allergen immunotherapy is the sole therapeutic option capable of modifying the natural course of allergic rhinitis and preventing the development of asthma. Results from paediatric patients are scarce. To evaluate the effectiveness and safety of a glutaraldehyde-modified extract of mites (Beltavac®) administered for one year under clinical routine conditions in children between 3 and 11 years old. Methods: This was a multicentre, prospective, 13-month cohort study. Among 97 children diagnosed with immunoglobulin E-mediated house dust mite allergic rhinoconjunctivitis, 87 initiated the subcutaneous immunotherapy. The main outcomes included the Combined Symptoms and Medication Score (CSMS), assessed for 1 month at baseline and after 1, 6, and 12 months, and the number of adverse reactions according to the WAO adverse reaction grading system. The levels of serum-specific immunoglobulins were also assessed. Results: CSMS improved scores throughout therapy (adjusted mean change and 95% confidence interval: 0.55, 0.26–0.84 points; p < 0.001). Improvements occurred in both children with (n = 68) and without asthma (n = 19), as well as in children aged ≥6 years (n = 76) and <6 years (n = 11), although statistical significance was not reached in the smallest subgroups. Eight children (9.2%) developed a total of 15 adverse reactions. Most occurred after the initial dose (five out of eight children), and were local (six out of eight) and minor (five out of eight). Over 90% of patients completed the full regimen. Conclusions: This study supports the effectiveness and safety of allergen immunotherapy administered according to a rush schedule for one year for paediatric allergic rhinitis.Keywords
Funding Information
- Probelte Pharma S.L.U.
This publication has 43 references indexed in Scilit:
- Allergic Rhinitis in Children and AdolescentsImmunology and Allergy Clinics of North America, 2021
- Mechanisms of Allergen Immunotherapy in Allergic RhinitisCurrent Allergy and Asthma Reports, 2020
- Mechanisms of allergen-specific immunotherapy and allergen toleranceAllergology International, 2020
- Calculation of confidence intervals for a finite population sizePharmaceutical Statistics, 2018
- Adherence to pharmacotherapy improves school performance in children with rhinitis and asthmaAllergologia et Immunopathologia, 2018
- The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescentsAnnals of Allergy, Asthma & Immunology, 2018
- Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective studyAllergologia et Immunopathologia, 2014
- Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading SystemJournal of Allergy and Clinical Immunology, 2010
- Burden of rhinitis in children with asthmaPediatric Pulmonology, 2005
- A long-term follow-up study of hyposensitization with immunoblottingJournal of Allergy and Clinical Immunology, 1990